AIMS OF THE STUDY: To assess the impact of olanzapine versus conventional neuroleptic therapy among subjects with schizophrenia on ratings of tardive dyskinesia (TD). METHOD: The naturalistic study was conducted in three psychiatric hospitals in Brazil. Patients had a diagnosis of schizophrenia and related disorders (DSMIV) and with a BPRS score>24. Patients were evaluated by means of the PANSS scale for symptomatology (Kay et al. 1986), the Clinical Global Impression, The UKU side effect rating scale (Lingjaerde et al. 1987), and the Tardive Dyskinesia AIMS scale (Guy et al. 1976). Patients were seen by the treating physician routinely while hospitalized and then monthly on an out-patient basis. All scale assessments were repeated after 9 months of discharge. RESULT: The sample was comprised of 190 patients (99 in theolanzapine and 91 in the standard treatment), with a completion rate of 88.2% for olanzapine and 84.9% for the conventional treatment (p=0.385, n. s.). The mean change from baseline in the PANSS total score favored olanzapine regarding negative symptoms (2.3, 95% C. I. 0.6-4.1, p<0.001); and general psychopathology (4.0, 95% C.I. 0.8-7.2, p<0.02) factors. TD was defined by applying Morgenstern & Glazer (1993) and Schooler & Kane (1982) criteria, on the basis of the AIMS scale. Both results favored olanzapine at the end of the follow-up (Morgenstern & Glazer: 25.6% versus 56.3%; Schooler & Kane: 16.3% versus 45.2%). At the end of the follow-up, by using the overall rating of the AIMS scale, the presence of TD was 2.3% for olanzapine (2/87), and 16.7% (12/72) for the conventional treatment. CONCLUSIONS: The results of this open label naturalistic trial showed that olanzapine had an impact on negative symptoms, decreased general psychopathology and reduced the risk of tardive dyskinesia.
RCT Entities:
AIMS OF THE STUDY: To assess the impact of olanzapine versus conventional neuroleptic therapy among subjects with schizophrenia on ratings of tardive dyskinesia (TD). METHOD: The naturalistic study was conducted in three psychiatric hospitals in Brazil. Patients had a diagnosis of schizophrenia and related disorders (DSMIV) and with a BPRS score>24. Patients were evaluated by means of the PANSS scale for symptomatology (Kay et al. 1986), the Clinical Global Impression, The UKU side effect rating scale (Lingjaerde et al. 1987), and the Tardive Dyskinesia AIMS scale (Guy et al. 1976). Patients were seen by the treating physician routinely while hospitalized and then monthly on an out-patient basis. All scale assessments were repeated after 9 months of discharge. RESULT: The sample was comprised of 190 patients (99 in the olanzapine and 91 in the standard treatment), with a completion rate of 88.2% for olanzapine and 84.9% for the conventional treatment (p=0.385, n. s.). The mean change from baseline in the PANSS total score favored olanzapine regarding negative symptoms (2.3, 95% C. I. 0.6-4.1, p<0.001); and general psychopathology (4.0, 95% C.I. 0.8-7.2, p<0.02) factors. TD was defined by applying Morgenstern & Glazer (1993) and Schooler & Kane (1982) criteria, on the basis of the AIMS scale. Both results favored olanzapine at the end of the follow-up (Morgenstern & Glazer: 25.6% versus 56.3%; Schooler & Kane: 16.3% versus 45.2%). At the end of the follow-up, by using the overall rating of the AIMS scale, the presence of TD was 2.3% for olanzapine (2/87), and 16.7% (12/72) for the conventional treatment. CONCLUSIONS: The results of this open label naturalistic trial showed that olanzapine had an impact on negative symptoms, decreased general psychopathology and reduced the risk of tardive dyskinesia.
Authors: C M Beasley; M A Dellva; R N Tamura; H Morgenstern; W M Glazer; K Ferguson; G D Tollefson Journal: Br J Psychiatry Date: 1999-01 Impact factor: 9.319
Authors: C M Beasley; S H Hamilton; A M Crawford; M A Dellva; G D Tollefson; P V Tran; O Blin; J N Beuzen Journal: Eur Neuropsychopharmacol Date: 1997-05 Impact factor: 4.600
Authors: G D Tollefson; C M Beasley; P V Tran; J S Street; J A Krueger; R N Tamura; K A Graffeo; M E Thieme Journal: Am J Psychiatry Date: 1997-04 Impact factor: 18.112
Authors: Stefan Gebhardt; Fabian Härtling; Markus Hanke; Markus Mittendorf; Frank M Theisen; Karin Wolf-Ostermann; Phillip Grant; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt Journal: Eur Child Adolesc Psychiatry Date: 2006-04-28 Impact factor: 4.785
Authors: Douglas L Noordsy; Shirley M Glynn; Catherine A Sugar; Christopher D O'Keefe; Stephen R Marder Journal: J Psychiatr Res Date: 2017-09-08 Impact factor: 4.791
Authors: Stefan Gebhardt; Fabian Härtling; Markus Hanke; Frank M Theisen; Richard von Georgi; Phillip Grant; Markus Mittendorf; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt Journal: Eur Child Adolesc Psychiatry Date: 2007-09-14 Impact factor: 4.785
Authors: Emily C Baron; Sujit D Rathod; Charlotte Hanlon; Martin Prince; Abebaw Fedaku; Fred Kigozi; Mark Jordans; Nagendra P Luitel; Girmay Medhin; Vaibhav Murhar; Juliet Nakku; Vikram Patel; Inge Petersen; One Selohilwe; Rahul Shidhaye; Joshua Ssebunnya; Mark Tomlinson; Crick Lund; Mary De Silva Journal: BMC Psychiatry Date: 2018-03-06 Impact factor: 3.630